Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 431.61K.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 431.61K.
Virada para Prejuízo
O desempenho da empresa passou a ser negativo, com prejuízo anual mais recente de US$ .
Avaliação Justa
O PE mais recente da empresa é -0.14, em uma faixa percentil média de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 2.00M ações, um aumento de 12.65% em relação ao trimestre anterior.